Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @KrystalBiotech
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @KrystalBiotech
-
We broke ground on a second cGMP facility for our
#GeneTherapy treatments for skin conditions. The Astra facility is intended to support potential commercial production of B-VEC, formerly KB103, as well as ongoing R&D efforts. Full details here: http://bit.ly/2GuRPHQ pic.twitter.com/Xk6pVCTYZX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are pleased to announce the strengthening of our team with Jennifer Chien joining the newly created CCO position. Ms. Chien brings more than 20 years commercial leadership experience that is critical as we look towards potential launch of KB103 in 2021:http://bit.ly/2tJ0cMT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today's
@Reuters article from@HamaraTamara and@CarlODonnell26 highlights#KrystalBiotech as one of 11 companies leading the way by making early investments in#GeneTherapy manufacturing, greatly streamlining the therapy development process. Read it here:https://reut.rs/2XUDEmYHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CEO Krish S. Krishnan will be presenting a corporate update at the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday December 3 at 9:10 a.m. ET. Webcast link for the presentation can be found here: http://bit.ly/34n1XfL
#GeneTherapy#Dermatologypic.twitter.com/clBSD005RV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We published a corporate update and third quarter 2019 financial results. Click here to see the full release: http://bit.ly/33lGLX9 and check http://ir.krystalbio.com/ for additional info.
$KRYSHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In the final data update from the Phase 1/2 trial of KB103, now B-VEC, the topical
#GeneTherapy induced rapid and durable wound closure in patients with dystrophic#EpidermolysisBullosa and was safe and well-tolerated. Read the full release here: http://bit.ly/2JxeaX4 pic.twitter.com/18PTKSILJC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We reinforced our IP portfolio with (1) a US patent for our platform technology, and (2) the first foreign patent (Australia) for our lead
#GeneTherapy product KB103. We remain committed to developing novel therapeutics for rare skin diseases. Full releasehttp://bit.ly/31l8O76Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The EMA Committee for Orphan Medicinal Products issued a positive opinion on our orphan designation application for KB105, our second
#GeneTherapy treatment, for patients with transglutaminase-1 deficient autosomal recessive congenital ichthyosis: http://bit.ly/2Vw6Cs8@EMANewspic.twitter.com/E2UKyCFn8J
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A new
#ClinicalTrial was just initiated and will study topical#GeneTherapy KB105 for treatment of#RareDisease transglutaminase-1 (TGM1) deficient autosomal recessive congenital#ichthyosis (ARCI). Read more about the trial here: http://bit.ly/2kr29Jy#dermatologypic.twitter.com/tKNm3DhWSX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CEO Krish Krishnan shares his advice with
@SBDealmakers on raising capital in#biotech and on how previous success in the industry paved the way for an initially self-funded company and a rapid IPO. Read the full story here: http://bit.ly/2Ur6jOV#DealmakersPittsburghpic.twitter.com/LgsQYMWB5b
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
KB103 study coordinator Dr. Peter Marinkovich was featured in
@TheDermEditor speaking about trial results, future plans and the hope this developmental#GeneTherapy could give to all those affected by dystrophic#EpidermolysisBullosa. Read it here: http://bit.ly/2TT5xKj pic.twitter.com/F5DFkHX5EF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Krystal reports second quarter 2019 financial results including recent milestones and program updates. Full release here: http://bit.ly/2T8Q0Wq
$KRYSpic.twitter.com/8DqfwE6i5n
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Data from the Phase 2 GEM2 study show that KB103 was well-tolerated and induced rapid & durable wound closure in adult & pediatric patients with dystrophic
#EpidermolysisBullosa. Granted RMAT designation paves way for a planned pivotal Phase 3 before 2020. http://bit.ly/2XDb4ct pic.twitter.com/cggoryLLsd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We submitted an IND for a new
#GeneTherapy candidate, KB105, for patients with the#RareDisease TGM-1 deficient autosomal recessive congenital ichthyosis (“ARCI”). Read the full release here: http://bit.ly/2WKEPYS#Ichthyosis$KRYSpic.twitter.com/NuF3ImekRf
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
KB103, our clinical-stage first-in-class topical
#GeneTherapy for the treatment of dystrophic#EpidermolysisBullosa, was granted PRIME eligibility by@EMA_News, allowing for frequent and early interactions with the EMA to accelerate development: http://bit.ly/2I0hs5g pic.twitter.com/iAJg5ZU5ta
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Krystal Biotech proslijedio/la je Tweet
.
@KrystalBiotech is currently recruiting patients onto their Phase 2 Study of KB103 (The GEM Study). KB103 is a topical gene therapy being evaluated in RDEB patients. For more information, please visit: http://debra.org/research-trials/KrystalBiotech/KB103 …pic.twitter.com/RwQ1fYqNZI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We celebrated the opening of Ancoris, our GMP facility for all production needs for KB103, our developmental
#GeneTherapy treatment for dystrophic#EpidermolysisBullosa. We were honored to be joined by@billpeduto@debraOfAmerica@SenToomey@SenBobCasey: http://bit.ly/2TzFBWm pic.twitter.com/55SCvUWY48
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join us in welcoming the newest member of our Board of Directors, Julian S Gangolli, whose vast experience with product launches will be invaluable as we progress our lead developmental product KB103 towards commercialization. For more details, see here: http://bit.ly/2VFK5bz pic.twitter.com/hvgp2Jo98Q
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A new article from
@BioPharmaReport highlights Ancoris, our state-of-the-art GMP facility designed to meet expected current and future research and production needs for lead developmental#GeneTherapy KB103, for#EpidermolysisBullosa. Read the story here:http://bit.ly/2GjHEYtHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our new state-of-the-art GMP facility, Ancoris, set to be the primary production site to meet projected research and commercial demand for KB103, was just completed. We're already planning a second facility to meet all future needs. Full news release here:http://bit.ly/2CpZPHn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.